Ilevro patents expiration

ILEVRO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7947295 NOVARTIS Ophthalmic compositions containing a synergistic combination of two polymers
Jun, 2024

(8 months from now)

US9662398 NOVARTIS Carboxylvinyl polymer-containing nanoparticle suspensions
Dec, 2030

(7 years from now)

US8921337 NOVARTIS Carboxyvinyl polymer-containing nanoparticle suspensions
Mar, 2032

(8 years from now)

Ilevro is owned by Novartis.

Ilevro contains Nepafenac.

Ilevro has a total of 3 drug patents out of which 0 drug patents have expired.

Ilevro was authorised for market use on 16 October, 2012.

Ilevro is available in suspension/drops;ophthalmic dosage forms.

The generics of Ilevro are possible to be released after 31 March, 2032.

Drugs and Companies using NEPAFENAC ingredient

Market Authorisation Date: 16 October, 2012

Treatment: NA


How can I launch a generic of ILEVRO before it's drug patent expiration?
More Information on Dosage

ILEVRO family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic